
Intelligent Bio Solutions Expects to Achieve 32.6% Gross Profit Expansion and Increased Profitability on Higher-Margin Sales
Gross profit expected to surge by 32.6% Unaudited revenue of $0.61 million for fiscal Q2 and $1.48 million for the
Gross profit expected to surge by 32.6% Unaudited revenue of $0.61 million for fiscal Q2 and $1.48 million for the
Multilingual upgrade will make INBS’ Drug Screening System accessible to over 4 billion users worldwide, including users across the Americas,
Quantum Traffic Management transitions from saliva and urine testing to non-invasive, in-house fingerprint sweat-based drug screening Most recent client added
NEW YORK, January 28, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering
Princebuild joins INBS’ portfolio of over 400 accounts in 19 countries as the Company plans to enter the US market
NEW YORK, December 18, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering
Intelligent Fingerprinting Drug Screening System on path to FDA 510(k) submission, expected in the fourth calendar quarter of 2024 INBS
The data from our pharmacokinetic (PK) study shows that fingerprint sweat mimics the rate and extent of codeine in blood
PK Study Successfully Demonstrates that Fingerprint Sweat Provides Reliable Sample for Drug Detection FDA 510(k) Clearance Would Enable the Introduction
Quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter, marking four consecutive quarters of year-on-year growth Higher-margin, recurring cartridge revenue surpassed
Digital Marketing Initiatives to Highlight Innovative Non-Invasive Drug Screening Technology and Market Expansion Plans NEW YORK, October 31, 2024 –
Unaudited quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter Higher-margin, recurring cartridge revenue expected to surpass reader revenue as primary
Developer Praises Intelligent Bio Solutions’ Innovative Drug Testing Solution for Improving Workplace Safety NEW YORK, October 24, 2024 – Intelligent
Transition will Minimize Downtime, Deliver Faster, More Cost-Effective Results, and Improve Overall Safety and Productivity NEW YORK, October 14, 2024
NEW YORK, October 09, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company